Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Evommune, Inc.NYSE: EVMN
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 282.0% from a year ago
Short-term investments stood at $163.15M at the end of Q1 FY2026, up 282.0% from a year earlier and up 55.2% from the prior quarter.
Context
- Short-term investments amounted to 50.6% of total assets at the end of Q1 FY2026, down 25.7 pp from a year earlier.
- Short-term investments increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +282.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 105.14M USD
- Year-over-year change
- +88.5%
- 2-year CAGR
- +44.9%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105.14M | +88.5% |
| FY2024 | 2024-12-31 | 55.79M | +11.4% |
| FY2023 | 2023-12-31 | 50.06M | — |
Short-term Investments vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 short-term investments of $163.15M is the 2nd highest of the 10 companies compared; the peer median is $28.57M.
- Its year-over-year change of +282.0% is the highest of 9, against a peer median of -38.3%.
- Short-term investments amounts to 50.6% of total assets for EVMN, versus a peer median of 16.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $351.06M | +87.1% | +49.6% | 16.1% | |
EVMNEvommune, Inc. | Mar 2026 | $163.15M | +282.0% | — | 50.6% |
| Mar 2026 | $144.83M | -37.8% | +61.0% | 50.3% | |
CLYMClimb Bio, Inc. | Mar 2026 | $101.21M | +46.6% | -6.5% | 66.4% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $65.83M | -51.4% | — | 62.1% |
| Mar 2026 | $28.57M | -31.1% | — | 22.1% | |
| Mar 2026 | $20.03M | -38.8% | -19.6% | 6.8% | |
FTREFortrea Holdings Inc. | Jun 2026 | $0 | — | — | 0.0% |
| Sep 2026 | $0 | -100.0% | +27.1% | 0.0% | |
| Mar 2026 | $0 | -100.0% | -71.8% | 0.0% | |
| Peer median (excluding EVMN) | $28.57M | -38.3% | +10.3% | 16.1% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.